

Referenties bulletin 2 2023

Artikel 1

De Ziektelastmeter voor astma

Referenties:

1. Slok et al. Effectiveness of the Assessment of Burden of COPD (ABC) tool on health-related quality of life in patients with COPD: a cluster randomised controlled trial in primary and hospital care. *BMJ Open*. 2016;6(7):e011519.
2. Slok et al. To use or not to use: experiences of healthcare professionals and patients with the Assessment of Burden of COPD (ABC) tool. *npj Primary Care Respiratory Medicine*. 2016;17;26:16074.
3. Boudewijns et al. ABC-tool reinvented: development of a disease-specific 'assessment of Burden of Chronic Conditions (ABCC)-tool' for multiple conditions. *BMC Family Practice*. 2020, 21(1), 1-7.
4. Claessens et al. Validity and reliability of the Assessment of Burden of Chronic Conditions (ABCC)-scale in the Netherlands. *Annals of Family Medicine*. 2023; 21(2); 103-111.

Artikel 2

Is het aantal circulerende eosinofielen **in het bloed** geschikt als biomarker om niet-geïndiceerd ICS gebruik terug te dringen bij COPD patiënten?

Referenties

- ^[1] van Schayck OC, Wesseling G, Schermer TR, Chavannes NH. Stoppen met ICS gebruik bij COPD-patiënten. *TPO-De Praktijk*. 2019;14(5):32-4.
- ^[1] GOLD. 2022 Global Strategy for Prevention, Diagnosis and Management of COPD: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2022 [Available from: <https://goldcopd.org/2022-gold-reports/>].

Artikel 3

Website keuzehulp inhalatiemedicatie

Referenties:

- 1 [Zinnige Zorg - Verbetersignalement Astma | Rapport | Zorginstituut Nederland \(link eruit halen\)](#)
- 2 [LAN Zorgpad inhalatiemedicatie 2019.pdf \(longalliantie.nl\)](#)

Artikel 4

Terugdringen van niet-gepast ICS-gebruik bij COPD: evaluatie van een regionale deïmplementatiestrategie in Drenthe.

Referenties

1. Bischoff E, Bouma M, Broekhuizen L, Donkers J, Hallensleben C, De Jong J, et al. NHG-Standaard COPD 2021 07-04-2023.
2. Fens T, van der Pol S, Kocks JWH, Postma MJ, van Boven JFM. Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. *Value Health*. 2019;22(10):1092-101.

3. van den Bemt L, van den Nieuwenhof L, Rutjes A, van der Meer V, Stege G, Wensing M, et al. Pragmatic trial on inhaled corticosteroid withdrawal in patients with COPD in general practice. *NPJ Prim Care Respir Med.* 2020;30(1):43.
4. Magnussen H, Lucas S, Lapperre T, Quint JK, Dandurand RJ, Roche N, et al. Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. *Respir Res.* 2021;22(1):25.
5. van Dulmen S, Kool T, E. V. Deimplementatiegids voor het terugdringen van niet-gepaste zorg in uw organisatie. Nijmegen: IQ HealthCare, Radboudumc; 2019.